Lokman Slim’s Sister to Asharq Al-Awsat: I Know Who Killed my Brother

Rasha al-Ameer, the sister of Lokman Slim, talks on the phone in Beirut. (Reuters)
Rasha al-Ameer, the sister of Lokman Slim, talks on the phone in Beirut. (Reuters)
TT

Lokman Slim’s Sister to Asharq Al-Awsat: I Know Who Killed my Brother

Rasha al-Ameer, the sister of Lokman Slim, talks on the phone in Beirut. (Reuters)
Rasha al-Ameer, the sister of Lokman Slim, talks on the phone in Beirut. (Reuters)

A silent pain reigns over the house of the family of Lokman Slim, an anti-Hezbollah activist, who was assassinated on Feb. 4.

At the entrance to the house, which is located in Beirut’s southern suburbs - Hezbollah’s stronghold - a lone policeman watches those visiting the grieving family.

Slim’s sister, Rasha al-Ameer, receives the mourners with the expression, “Lokman is alive,” with a smile on her face that disappears only when she sees someone dear to her slain brother crying; then, her eyes fill with tears, even for a moment.

“He is the brother, the friend, the teacher, and the example,” al-Ameer told Asharq Al-Awsat, adding: “No one can kill ideas, opinions and values. They killed my brother, so let them tell me how they will kill or erase his thoughts, actions and values.”

She says that Slim chose the more difficult road, the path of true freedom, away from slogans and bargains.

“My brother was killed because his words were painful to them, because he was frank, tough and did not compromise. They found him disturbing. They want to monopolize values and consider themselves the strongest, so how can my brother’s voice come out of their monopoly? They didn’t bear this.”

Al-Ameer doesn’t want to know the truth, and she is not expecting anything from the Lebanese judiciary, which she says is “in a coma”. She also does not want an international investigation, especially since it is also not always free from political interference, as she says.

She affirms that she will not resort to an international investigation - not only because it requires certain conditions and a mechanism that passes through the parliament - but because she knows well who killed her brother.

“I don’t care about the police details. What will the judiciary tell me? What kind of bullets were used to kill my brother? How did they deceive him and he resisted? These are disgusting details that I don’t want to know… They will not ease the burden of my loss. I know the truth and this is enough,” she says.

As she speaks to Asharq Al-Awsat, al-Ameer repeats a verse from the Bible, when Jesus says: “Love your enemies, bless them that curse you, do good to them that hate you…”

But she adds: “It is too early to talk about forgiveness now, I cannot, but I always think about how a person can live with his enemies, I think deeply about this matter, how I can accept them after what they have done.”

“My brother worked a lot on how to reconcile the Lebanese after the civil war and the massacres they committed against each other. He worked on the so-called transitional justice that transcends those who killed whoever…” she recounts.

Al-Ameer did not like to comment on the reports that have spread recently about the reasons for Slim’s killing, including that he was working on a specific file related to Hezbollah and money laundering.

“Let them come up with their arguments, I don't know,” she says.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.